Ganga PharmaceuticalsShare price, financial results, shareholding and management
- Market cap
- ₹7 cr
- Stock P/E
- 73.9peers 17.4
- Book value
- ₹14.1
- Price to book
- 0.89
- EV / operating profit
- -
- Market cap to sales
- 2.61
- ROCE · FY26
- 2.9%
- ROE · FY26
- 1.3%
- ROE, 3-year average
- 1.1%
- Operating margin · FY26
- 1.4%peers 13.2%
- Sales growth, 3 years
- 3.0%
- Profit growth, 3 years
- 35.7%
- Debt to equity
- 0.13peers 0.38
- Borrowings
- ₹1.1 cr
- Interest cover
- 2.0×
- Cash from business / op. profit
- -3275%
- Debtor days
- 129
- Pledged
- 0.00%
- Promoter holding
- 50.91%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 365
- 52-week high / low
- ₹14 / ₹9
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Ganga Pharmaceuticals share price chart
Close on 8 Sept 2026 · +4.17% on the day · Vol 16,000
Daily prices to 8 Sept 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 8 Sept 2026
- 1 year
- -14.4%
- Traded a day, 20 days
- ₹0.02 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +7% | +25% |
| 3 years, a year | +3% | +36% |
| Latest half, H2 FY26 | +10% | +33% |
Ganga Pharmaceuticals revenue and profit growth
Half-yearly results · Profit and lossSales have grown slowly. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Ganga Pharmaceuticals half-yearly results
SME companies report every six months · ₹ crore
| H1FY23 | H2FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.35 | 1.24 | 1.32 | 1.42 | 1.31 | 1.33 | 1.37 | 1.46 |
| Expenses | 1.28 | 1.30 | 1.27 | 1.41 | 1.42 | 1.33 | 1.39 | 1.40 |
| Operating profit | 0.07 | -0.07 | 0.05 | 0 | -0.11 | 0 | -0.02 | 0.06 |
| OPM | 5.5% | -5.6% | 3.9% | 0.3% | -8.6% | -0.3% | -1.6% | 4.2% |
| Interest | 0.12 | 0.07 | 0.09 | 0.09 | 0.09 | 0.09 | 0.07 | 0.07 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| Profit before tax | 0.04 | 0.01 | 0.02 | 0.04 | 0.07 | 0.03 | 0.03 | 0.10 |
| Net profit | 0.03 | 0.01 | 0.02 | 0.03 | 0.02 | 0.06 | 0.03 | 0.08 |
Ganga Pharmaceuticals profit and loss
Full years to March, FY15 to FY26 · ₹ crore, consolidated where reported
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.44 | 2.45 | 2.63 | 2.73 | 3.18 | 3.08 | 2.37 | 2.32 | 2.59 | 2.74 | 2.64 | 2.83 |
| Expenses | 2.19 | 2.15 | 2.32 | 2.41 | 2.76 | 2.70 | 2.34 | 2.28 | 2.58 | 2.68 | 2.75 | 2.79 |
| Operating profit | 0.25 | 0.30 | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | 0 | 0.06 | -0.12 | 0.04 |
| OPM | 10.3% | 12.2% | 11.8% | 11.7% | 13.2% | 12.3% | 1.3% | 1.7% | 0.2% | 2.1% | -4.4% | 1.4% |
| Other income | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.17 | 0.25 | 0.26 | 0.30 | 0.24 | 0.44 | 0.28 |
| Interest | 0.33 | 0.33 | 0.32 | 0.28 | 0.25 | 0.24 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 | 0.13 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.06 |
| Profit before tax | 0.05 | 0.07 | 0.11 | 0.13 | 0.26 | 0.26 | 0.04 | 0.06 | 0.05 | 0.06 | 0.10 | 0.13 |
| Tax rate | 40.0% | 28.6% | 27.3% | 23.1% | 30.8% | 23.1% | 50.0% | 16.7% | 26.4% | 27.0% | 16.8% | 21.7% |
| Net profit | 0.03 | 0.05 | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 | 0.10 |
| EPS ₹ | 0.13 | 0.12 | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.10 | 0.10 | 0.11 | 0.16 | 0.17 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Earnings per share before FY21 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Ganga Pharmaceuticals profitability
Margins and returns on capitalLast year the company kept more from each rupee of sales than the year before. It earns a low return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 10.3% | 12.2% | 11.8% | 11.7% | 13.2% | 12.3% | 1.3% | 1.7% | 0.2% | 2.1% | -4.4% | 1.4% |
| Tax rate | 40.0% | 28.6% | 27.3% | 23.1% | 30.8% | 23.1% | 50.0% | 16.7% | 26.4% | 27.0% | 16.8% | 21.7% |
| ROCE | · | 6.8% | 6.1% | 5.8% | 7.3% | 7.2% | 3.4% | 3.5% | 3.3% | 3.1% | 3.3% | 2.9% |
| ROE | · | 1.3% | 1.4% | 1.8% | 3.8% | 3.6% | 0.4% | 0.7% | 0.7% | 0.8% | 1.1% | 1.3% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ganga Pharmaceuticals debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. It cut its borrowings last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. Customers take about as long to pay as they did in FY24.
Bars below the line are cash going out.
Ganga Pharmaceuticals balance sheet
At each 31 March · ₹ crore
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 2.33 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 | 5.91 |
| Reserves | 0.31 | 0.74 | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 | 2.40 |
| Net worth | 2.64 | 4.80 | 4.87 | 4.97 | 5.15 | 5.35 | 5.37 | 5.41 | 5.45 | 7.05 | 7.13 | 8.31 |
| Borrowings | 2.14 | 2.19 | 2.14 | 2.05 | 1.87 | 1.45 | 1.55 | 1.93 | 1.83 | 1.36 | 1.42 | 1.09 |
| Other liabilities | 0.61 | 0.35 | 0.60 | 1.22 | 0.74 | 0.77 | 0.74 | 0.66 | 0.71 | 0.24 | 0.42 | 0.25 |
| Total liabilities | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8 | 7.99 | 8.65 | 8.97 | 9.65 |
| Fixed assets | 0.65 | 0.62 | 0.62 | 0.82 | 0.80 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | 0.65 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.05 | 0.50 | 0 | 0 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0 | 0 |
| Other assets | 4.69 | 6.22 | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | 9 |
Ganga Pharmaceuticals cash flow
₹ crore
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.27 | -1.05 | 0.05 | 0.24 | 0.11 | -0.31 | -0.18 | -0.21 | -0.04 | -1.26 | -0.58 | -1.31 |
| Cash from investing | -0.18 | -0.83 | 0.62 | -0.14 | 0.28 | 0.37 | 0.28 | 0.19 | 0.49 | 0.13 | 1.18 | 0.24 |
| Cash from financing | -0.06 | 1.90 | -0.33 | -0.36 | -0.45 | -0.29 | -0.10 | 0.03 | -0.44 | 1.14 | -0.33 | 0.82 |
| Net cash flow | 0.03 | 0.02 | 0.34 | -0.26 | -0.06 | -0.23 | 0 | 0.01 | 0.01 | 0.01 | 0.27 | -0.25 |
Working capital
Days
| FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 109 | 140 | 173 | 211 | 141 | 127 | 126 | 140 | 132 | 130 | 134 | 129 |
| Inventory days | 288 | 375 | 386 | 359 | 341 | 297 | 333 | 331 | 347 | 362 | 353 | 329 |
| Days payable | 118 | 99 | 183 | 330 | 163 | 160 | 130 | 152 | 171 | 29 | 84 | 34 |
| Cash conversion cycle | 279 | 416 | 377 | 240 | 319 | 264 | 329 | 318 | 308 | 463 | 403 | 423 |
| Working capital days | 142 | 468 | 429 | 417 | 388 | 331 | 457 | 503 | 477 | 639 | 731 | 856 |
Ganga Pharmaceuticals peers and competitors
Listed SME companies in the same industryBy sales, Ganga Pharmaceuticals is number 34 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Bio Medica Laboratories | 205 | 17.4 | 43.1 | 11.8 | 45.6% | 1.51 |
| Himalaya Nutravedics India | 127 | 17.1 | 43.1 | 7.4 | 18.8% | 0.31 |
| Amwill Health Care | 89 | 8.0 | 43 | 11 | 30.0% | 0.00 |
| Vilin Bio Med | 79 | 41.1 | 42.3 | 1.9 | 7.6% | 0.01 |
| Accretion Nutraveda | 214 | 42.1 | 33.6 | 5.1 | 20.5% | 0.12 |
| Goldline Pharmaceutical | 30 | 7.4 | 31.2 | 4.1 | 22.7% | 0.88 |
| Cian Healthcare | 67 | - | 28 | -23 | -24.0% | 3.22 |
| Asston Pharmaceuticals | 83 | 21.5 | 25.5 | 3.9 | -2.0% | 0.13 |
| Medicamen Organics | 39 | - | 22.6 | -4 | -16.6% | 0.50 |
| Fabino Enterprises | 4 | - | 20.8 | -0.6 | -9.9% | 0.44 |
| Ganga Pharmaceuticals | 7 | 73.9 | 2.8 | 0.1 | 1.4% | 0.13 |
| Median of the 10 others | 81 | 17.4 | 32.4 | 4 | 13.2% | 0.38 |
Ganga Pharmaceuticals shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Ganga Pharmaceuticals shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 22 | Mar 23 | Sep 23 | Mar 24 | Sep 24 | Mar 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.71% | 66.71% | 66.71% | 56.02% | 56.02% | 56.02% | 50.91% | 50.91% |
| Number of shareholders | 355 | 356 | 359 | 363 | 365 | 368 | 366 | 365 |
Ganga Pharmaceuticals latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹1.5 cr (+10%), net profit ₹0.1 cr (+33%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 50.91%.
Ganga Pharmaceuticals announcements
5 on record, latest first; each opens the filing on the exchange
- Company UpdateCertificate in terms of Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026PDF ↗
- Company UpdateRe-appointment of Managing DirectorPDF ↗
- AGM/EGMVoting Results of 37th Annual General Meeting along with the Scrutinizer ReportPDF ↗
- Insider Trading / SASTClosure of Trading WindowPDF ↗
- AGM/EGMProceeding of the AGM held on Saturday, September 26, 2026PDF ↗
Ganga Pharmaceuticals annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Ganga Pharmaceuticals share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Ganga Pharmaceuticals' data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- iThe shares traded on only 6 days in the past year, so the price, its range and the returns here rest on few trades.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (59,11,500 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY15 to FY26.
- iPrices run to the close on 8 Sept 2026, from the exchange's daily figures.
Questions people ask about Ganga Pharmaceuticals
What does Ganga Pharmaceuticals do?
Ganga Pharmaceuticals is an SME company listed on BSE SME, in pharmaceuticals & biotechnology.
What is the share price of Ganga Pharmaceuticals?
₹12.5 at the close on 8 Sept 2026, from the exchange's daily figures.
What is the market cap of Ganga Pharmaceuticals?
₹7 cr at the close on 8 Sept 2026, on 59,11,500 shares.
What is the P/E of Ganga Pharmaceuticals?
73.9 times FY26 profit at the close on 8 Sept 2026 (our arithmetic).
What are Ganga Pharmaceuticals' revenue and profit?
Revenue ₹3 cr and profit after tax ₹0 cr in FY26.
Who are the promoters of Ganga Pharmaceuticals?
The promoter group; promoters held 50.91% at 31 March 2026.
What is Ganga Pharmaceuticals' website?
www.ayurvedganga.com
More SME companies like Ganga Pharmaceuticals
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Dipna PharmachemDPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹11 cr
- Fabino EnterprisesFABINO · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹4 cr
- Sunrest LifescienceSUNREST · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹15 cr
- Mono PharmacareMONOPHARMA · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹18 cr
- Walpar NutritionsWALPAR · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2021Market cap ₹24 cr
- Goldline PharmaceuticalGLPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹30 cr
Every listed SME company in Pharmaceuticals & Biotechnology →
Built from 5 exchange announcements, 8 shareholding patterns and 12 years of reported results. Every figure carries its source; where the documents are silent, the page says so.